About CorVista Health
CorVista Health is transforming cardiovascular diagnostics by bringing hospital-grade testing to primary care settings. The company addresses a critical gap in cardiovascular care: 69% of heart failure cases are misdiagnosed in primary care, 51% of pulmonary arterial hypertension cases in the U.S. are misdiagnosed, and 41% of heart attack patients had previously undiagnosed coronary artery disease. CorVista's technology fuses data science with disease biology to detect subtle physiologic changes, quantify autonomic patterns, systemic stress, and vascular dynamics at the point of care. The system tests for multiple cardiovascular conditions simultaneously, helping healthcare providers identify previously overlooked conditions before symptoms escalate. The company's mission is to transform cardiovascular care by moving diagnosis out of the hospital and into the doctor's office, eliminating barriers, reducing delays, and ensuring every patient receives timely, accurate diagnoses. The CorVista System with CAD Add-on and PH Add-on has received 510(k) clearance from the FDA. The technology is developed and manufactured by Analytics For Life, Inc., and licensed exclusively to CorVista Health.
Mission & Story
Mission
To transform cardiovascular care by moving diagnosis out of the hospital and into the doctor's office
Clinical Focus
Medical conditions and clinical areas addressed by CorVista Health.
Who It Serves
Milestones & Awards
Recent Milestones
Appointed Nikki Troiano Gainey as Chief Customer Officer and Ian Shadforth as Chief Strategy Officer (May 2026). Announced collaboration with Mayo Clinic for pulmonary hypertension diagnosis (April 2026). Demonstrated high-sensitivity CAD detection including INOCA at ACC.26 conference (March 2026).
Key Partnerships
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.